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Abstract
Background: Patients with psoriatic arthritis (PsA) experience functional impairment and reduced quality of life,
and thus patient global assessment in PsA is explained mainly by the physical, but also by the psychological,
aspect of the disease. To assess the prevalence of minimal disease activity (MDA) in Spanish patients with PsA,
we examined their characteristics and the association between MDA and the impact of the disease as assessed
by the PsA Impact of Disease (PsAID) questionnaire.
Methods: A cross-sectional multicenter study was carried out in patients who fulfilled the Classification for
Psoriatic Arthritis (CASPAR) criteria with at least 1 year of disease duration, and who were treated with biological or
conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) according to routine clinical practice
in Spain. Patients were considered in MDA if they met at least 5/7 of the MDA criteria. The association between
MDA and the recently developed PsAID questionnaire was also recorded.
Results: Of 227 patients included, 133 (58.6%) were in the MDA state (52% with antitumor necrosis factor (anti-TNF)
α monotherapy, 24% with csDMARD monotherapy, and 24% with anti-TNFα in combination with csDMARD). Using
multivariate logistic regression analysis, male gender (odds ratio (OR) 2.74, p = 0.001), a sedentary lifestyle (OR 3.13,
p = 0.002), familial history of PsA (OR 0.38, p = 0.036), C-reactive protein (CRP) level (OR 0.92, p = 0.010), and use of
corticoids (OR 0.33, p = 0.007) were considered features related to MDA. MDA patients had a significantly lower
impact of the disease according to PsAID (mean total score (SD): MDA 3.3 (3.1) vs. non-MDA 7.1 (5.2); p < 0.001).
Conclusions: Nearly 60% of Spanish PsA patients achieve MDA in routine clinical practice. MDA remains one of the
most useful therapeutic targets for PsA since patients who reached this state also had a significantly lower impact
of disease according to PsAID.
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Background
Psoriatic arthritis (PsA) is a chronic inflammatory
musculoskeletal disease that is usually seronegative for
rheumatoid factor, associated with psoriasis, and with a
prevalence of 0.02–0.42% in the general population and
13.8–30% among patients with psoriasis [1, 2]. PsA is a
heterogeneous condition with articular and extra-articular
manifestations including a combination of peripheral
arthritis, axial disease, enthesitis, dactylitis, and skin and
nail disease.
The target of therapy for PsA is to reach a state of
remission or, at least, minimal disease activity (MDA).
For patients with PsA, the heterogeneity among disease
manifestations as well as the need to validate outcome
measures makes the definition of remission challenging
[3]. Clinical remission requires achieving disease quies-
cence in all disease domains [3]. In 2010, Coates et al.
[4] developed a composite outcome measure as a target
of treatment for patients with PsA that encompasses
most of the disease domains. These criteria for MDA
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were validated using interventional trial data [5].
Recent studies have found that MDA could be a reliable
target for antitumor necrosis factor alpha (anti-TNF)
therapy [6–8].
PsA has a high impact on the lives of patients [9, 10].
Patients with PsA experience significant disability and
reduced quality of life, resulting from emotional distress
and functional impairment associated with psoriatic skin
lesions, as well as arthritis-related joint pain [9, 10]. A
prominent benefit of treatment with anti-TNF in PsA
patients has been an improvement in patient-reported
outcomes (PROs), including health-related quality of life
[11]. Recently Gossec et al. have developed and validated
the PsA Impact of Disease (PsAID) questionnaire which
can be used to calculate a score reflecting the impact of
PsA on the lives of patients [12].
Measures that assess outcomes in rheumatic diseases
should not only capture the major domains of the
disease, but also capture the vision of the patient for
improvement in their overall health. The aim of this
study was to determine the MDA rate in patients with
PsA, to describe their characteristics, and to evaluate the
association between MDA and the impact of the disease
as assessed by the PsAID questionnaire in routine
clinical practice.
Methods
This was an observational, cross-sectional, multicenter
study carried out at twenty-five rheumatology outpatient
clinics over the whole of Spain. The study included outpa-
tients of both genders over 18 years of age diagnosed with
PsA according to the Classification for Psoriatic Arthritis
(CASPAR) criteria [13] with at least 1 year of disease
duration, with hand and foot radiological tests carried out
during the 6 months prior to the study visit, and receiving
treatment with biological and conventional synthetic (cs)
disease-modifying anti-rheumatic drugs (DMARDs).
All patients provided their informed written consent.
In accordance with Spanish recommendations, the study
was approved by the Clinical Research Ethics Committee
of La Fe Hospital and was conducted in accordance with
the principles contained in the Declaration of Helsinki
for studies in humans. Data were collected between May
2014 and February 2015 at a single visit.
Patient data collection included demographics and
clinical characteristics (age, sex, body mass index, educa-
tional level and employment status, toxic habits, and co-
morbidities), detailed PsA clinical history (evolution time
of PsA, time from onset of skin and articular symptoms,
pattern of PsA at onset (peripheral, axial, mixed), enthe-
sitis, dactylitis, involvement of distal interphalangeal
joint, familial history (psoriasis, PsA, ankylosing spondyl-
itis, others), C-reactive protein (CRP) levels, erythrocyte
sedimentation rate (ESR), positive human leukocyte
antigen-B27 (HLA-B27)), and record of current use of
medications (nonsteroidal anti-inflammatory drugs
(NSAIDs), infiltrations, biological and csDMARDs, and
corticoids). Radiological findings (erosions in hands and
feet, joint space narrowing on hands or feet, sacroilitis,
syndesmophytes) from radiological tests carried out
during the 6 months prior to the study visit were also
recorded. The Psoriasis Area Severity index (PASI) [14]
was assessed. In addition, patients completed self-
reported questionnaires including the Health Assess-
ment Questionnaire (HAQ) [15], the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) [16], and
the PsAID [12].
Patients were considered in MDA when they met ≥5
of the following criteria: tender joint count ≤1, swollen
joint count ≤1, PASI score ≤1 or body surface area ≤3%,
patient pain visual analog scale (VAS) score ≤15, patient
global disease activity VAS score ≤20, HAQ score ≤0.5,
and tender entheseal points ≤1.
The PsAID questionnaire [12] reflects the impact of PsA
from the perspective of the patient. It is comprised of 12
physical and psychological domains. Each domain is rated
from 0 to 10 with a different weighting. The total score is
divided by 20. The final score has a range from 0 (best
status) to 10 (worst status) with a cutoff of 4 [12].
Statistical methodology
A descriptive statistical analysis of all the variables was
performed, including central tendency and dispersion
measures for continuous variables, and absolute and
relative frequencies for categorical variables. Patients
were analyzed and distributed into two groups according
to MDA status. Student's t test, Mann-Whitney U test
or Kruskall Wallis H test were used to compare quanti-
tative variables and Pearson’s chi-square or Fisher exact
tests were used for qualitative variables. Univariate and
multivariate models were carried out to identify factors
independently associated with MDA. Tests were two-
tailed with a significance level of 5%. Data were analyzed
using SPSS V19.0 statistical software.
Results
Of the 227 included patients, 133 (58.6%) were in MDA at
the study visit. Figure 1 shows the proportion of patients
that fulfilled each MDA criterion according to MDA state.
The most common active domains were global disease
activity VAS score ≤20 and HAQ <0.5, achieved by 58.6%
and 77.4% of MDA patients, respectively (Fig. 1).
Demographic and clinical characteristics of the study
population with respect to the presence of MDA are
shown in Table 1. Most of the patients were men
(54.2%) with a mean (SD) age of 53.2 (12.4) years. Over-
all, 57.7% (MDA 47.9% vs. non-MDA 57.4%; p = 0.197)
of patients suffered from at least one concomitant
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disease, the most frequent being dislipemia (MDA 33.1%
vs. non-MDA 26.6%; p = 0.295), hypertension (MDA
26.3% vs. non-MDA 28.7%; p = 0.688), and obesity
(MDA 24.1% vs. non-MDA 17.0%; p = 0.201; Table 1).
Of the total patients, 54.6% were employed (MDA
60.9% vs. non-MDA 45.7%) and 5.7% had temporary or
full disability to work due to PsA (MDA 1.5% vs. non-
MDA 11.7%; p < 0.001). Regarding PsA condition, 83.3%
of the patients were diagnosed with peripheral disease
(oligoarticular 51.6%, polyarticular 48.4%). Dactylitis,
enthesitis, and distal interphalangeal joints were detected
in 49.3%, 35.7%, and 41.0% of patients, respectively.
Overall, 49.3% of the patients had familial history of
psoriasis, and 12.3% had a history of PsA, which was
significantly more frequent in non-MDA patients than
in those who achieved the MDA state (19.1% vs. 7.5%;
p < 0.05; Table 1). Disease duration was 9.6 (7.7) years
and the musculoskeletal symptoms onset occurred
nearly 10 years after the skin symptoms appeared
(Table 1). At the study visit, MDA patients had fewer hand
erosions than non-MDA patients (30.8% vs. 44.7%; p < 0.05;
Table 1). The mean (SD) CRP level was 3.6 (6.2) mg/L,
(MDA 2.8 (3.9) mg/L vs. non-MDA 4.7 (8.2) mg/L; p < 0.05),
the mean (SD) ESR value was 14.76 (12.4) mm/h, and 23
(17.6%) of 131 patients tested for HLA-B27 were positive.
MDA patients had a significantly lower impact of the
disease as measured by PsAID (MDA 3.3 (3.1) vs. non-
MDA 7.1 (5.2); p < 0.001; Table 1). Eighty-eight (66.7%) of
MDA patients vs. 34 (37.4%) of non-MDA patients
obtained a PsAID score <4 (p < 0.0001). Statistically
significant differences were observed between MDA and
non-MDA patients for all PsAID domains (p < 0.001;
Fig. 2). Similarly, patients with MDA presented a
significantly lower total score on PASI, BASDAI, and
HAQ questionnaires compared with those who had not
achieved MDA (p < 0.001; Table 1).
Multivariate analysis showed that male gender in-
creased the odds of having achieved MDA (odds ratio
(95% confidence interval) 2.75 (1.47–5.12); p = 0.001) as
well as living a sedentary life (3.13 (1.50–6.53); p =
0.002), while having a familial history of PsA (0.39
(0.16–0.94); p = 0.038), current elevated CRP level (0.92
(0.86–0.98); p = 0.010) or use of corticosteroids (0.33
(0.15–0.74); p = 0.007) decreased the odds of having
achieved MDA (Table 2).
Treatments at the study visit are shown in Table 3.
MDA was achieved by 62.7% of the patients who re-
ceived anti-TNF alone, by 52.5% receiving anti-TNF plus
csDMARDs treatment, and by 62.7% receiving mono-
therapy with csDMARDS (Table 3). Overall, the most
frequent anti-TNFs used were etanercept (37.5%) and
adalimumab (31.3%), and among the csDMARDs the
most common was methotrexate (76.0%).
Statistically significant differences were not observed
between non-MDA and MDA patients regarding use of
any kind of treatment with the exception of corticoids
(Table 3). The proportion of patients who received
corticoids was significantly higher among non-MDA
than MDA patients (59% non-MDA vs. 41% MDA;
p < 0.05; Table 3).
Discussion
Remission or low disease activity is the goal of therapy
in PsA. In this study, 58.6% of the patients were in a
MDA state. This prevalence is in concordance with that
reported in other studies [6–8]. Recent prospective stud-
ies, also carried out in the clinical setting, demonstrated
that up to 64% of patients treated with anti-TNFα drugs
achieved MDA after 12 months [6–8]. A similar rate
(60%) was also reported in a PsA cohort of 344 patients
receiving biological and non-biological DMARDs [17].
Fig. 1 MDA criteria according to MDA state. HAQ Health Assessment Questionnaire, MDA minimal disease activity, PASI Psoriasis Area and Severity
Index, VAS Visual analogue scale
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The less frequently achieved MDA criteria by the
MDA population were patient global disease activity
VAS score ≤20 and HAQ <0.5; this latter measure
focused on physical disability and pain. This finding is in
line with previous results [6], and might reflect the
patient’s perception not only of damage but also of
active disease. In fact, meeting MDA criteria does not
exclude the presence of a small amount of disease activ-
ity [17]. However, MDA is a good therapeutic target in
PsA, as patients who reach this state have better func-
tional status and lower impact of disease.
In line with our results, male sex has been identified
previously as a predictor not only of MDA [18] but also
of response to treatment with anti-TNFα therapy [6–8].
However, we found that a sedentary lifestyle is a
factor associated with MDA, which could be in
contradiction with previous studies where obesity and
metabolic syndrome have been associated with a
lower probability of achieving MDA [19–21]. Indeed,
the benefit of programs that encourage physical activ-
ity has been reported recently [22]. Although unex-
pected and controversial, according to the hypothesis
that mechanical stress is associated with musculoskeletal
inflammation, a sedentary lifestyle in PsA could reduce
clinical complications associated with strenuous physical
activity [23].








Male, n (%) 123 (54.2) 82 (61.7) 41 (43.6) <0.05
Age, mean (SD), years 53.2 (12.4) 53.5 (13.3) 52.8 (10.9) NS
Smoker, n (%) 41 (18.1) 19 (14.3) 22 (23.4) NS
Comorbidities, n (%)
Dyslipemia 69 (30.4) 44 (33.1) 25 (26.6) NS
HBP 62 (27.3) 35 (26.3) 27 (28.7) NS
Obesity 48 (21.1) 32 (24.1) 16 (17.0) NS
DM 23 (10.1) 15 (11.3) 8 (8.5) NS
PsA characteristics
PsA clinical pattern, n (%) NS
Axial 8 (3.5) 3 (2.3) 5 (5.3)
Peripheral 189 (83.3) 113 (85.0) 76 (80.9)
Mixed 30 (13.2) 17 (12.8) 13 (13.8)
Familial history, n (%)
Psoriasis 112 (49.3) 64 (48.1) 48 (51.1) NS
PsA 28 (12.3) 10 (7.5) 18 (19.1) <0.05
Ankylosing spondylitis 2 (0.9) 2 (1.5) 0 (0.0) NS
PsA duration, mean (SD), years 9.6 (7.7) 9.80 (8.1) 9.38 (7.3) NS
Skin symptoms duration, mean (SD), years 22.1 (14.7) 20.6 (14.3) 24.2 (15.1) NS
Articular symptoms duration, mean (SD), years 12.1 (9.3) 11.8 (8.8) 12.7 (9.9) NS
PsA status at study visit
Radiologic findings
Erosions in hands, n (%) 83 (36.6) 41 (30.8) 42 (44.7) <0.05
Joint in hands with erosion, mean (SD) 4.3 (4.2) 4.9 (4.5) 3.7 (3.9) NS
Erosions in feet, n (%) 67 (29.5) 38 (28.6) 29 (30.9) NS
Joint in feet with erosion, mean (SD) 3.7 (3.4) 3.9 (3.3) 3.5 (3.7) NS
PsAID, mean (SD) 4.9 (4.5) 3.3 (3.1) 7.1 (5.2)) <0.001
PASI, mean (SD) 1.6 (3.8) 0.9 (1.6) 2.8 (5.7) <0.05
BASDAI*, mean (SD) 2.8 (2.4) 2.0 (1.8) 3.6 (2.5) <0.001
HAQ, mean (SD) 0.8 (0.6) 0.3 (0.5) 0.5 (0.6) <0.001
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, DM diabetes mellitus, HAQ Health Assessment Questionnaire, HBP high blood pressure, MDA minimal
disease activity, NS not significant, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, PsAID Psoriatic Arthritis Impact of Disease, SD standard deviation.
*Performed only in subjects with axial disease
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There has been evidence of genetic predisposition
to PsA, although there is no specific gene for the
disease [24, 25]. In our study, the presence of a
familial history of PsA was related with non-MDA. It
may represent an effect of genetics both in the sever-
ity and in the capability to respond to drugs, although
it is an open thesis that calls for additional research.
On the contrary, in our study having a familial
history of psoriasis did not present a relationship with
MDA. Similarly, a recent study showed that the sever-
ity of psoriasis and the proportion of patients with
comorbidities were not affected by the presence of a
family history of psoriasis [26].
In PsA, the most common inflammatory indicators
(ESR and CRP) used for the evaluation of disease activity
in rheumatoid arthritis are within normal levels in half
of the patients [27]. However, when these two markers
are increased, their utility is undeniable [27]. Baseline
high CRP and ESR are predictors for MDA [6].
Table 2 Multivariate logistic regression analysis
p value Adjusted OR (95% CI)
Sex (men) 0.001 2.746 (1.473–5.119)
Sedentary lifestyle 0.002 3.127 (1.497–6.534)
PsA familial history 0.038 0.387 (0.159–0.938)
C-reactive protein 0.010 0.920 (0.864–0.980)
Corticoids 0.007 0.335 (0.151–0.745)
CI confidence interval, PsA psoriatic arthritis, OR odds ratio
Table 3 PsA treatment at study visit
Total MDA No MDA p
Treatment pattern, n (%) NS
Anti-TNF monotherapy 110 69 (62.7) 41 (37.3)
DMARDS and anti-TNF 61 32 (52.5) 29 (47.5)
DMARDS monotherapy 51 32 (62.7) 19 (37.3)
Anti-TNF*, n (%) 112 64 (57.1) 48 (42.9) NS
Etanercept 42 26 (61.9) 16 (38.1)
Adalimumab 35 22 (62.9) 13 (37.1)
Infliximab 15 6 (40.0) 9 (60.0)
Golimumab 13 7 (53.8) 6 (46.2)
Mean (SD) time, months 45.7 (34.7) 50.5 (35.0) 40.2 (33.8) NS
DMARDS*, n (%) 171 101 (59.1) 70 (40.9) NS
Metotrexate 130 76 (58.5) 54 (41.5)
Leflunomide 32 17 (53.1) 15 (46.9)
Mean (SD) time, months 73.7 (70.4) 71.8 (71.8) 76.4 (69.7) NS
NSAIDs**, n (%) 114 62 (54.4) 52 (45.6) NS
Infiltrations**, n (%) 48 27 (56.3) 21 (43.8) NS
Corticoids**, n (%) 39 16 (41.0) 23 (59.0) <0.05
*Monotherapy or combination therapy
**Combination therapy
anti-TNF anti-tumor necrosis factor, DMARDS disease-modifying anti-rheumatic
drugs, NS not significant, NSAIDs nonsteroidal anti-inflammatory drugs
Fig. 2 Psoriatic Arthritis Impact of Disease (PsAID) score according to minimal disease activity (MDA) state
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Conversely, in this cross-sectional study, we found that
having increased CRP level at the study visit has a
very slight relationship to non-MDA status. Being a
transversal study, it may only reflect the patients who
are in a state of greater activity.
We also identified use of therapy with corticoids as a
possible factor related to non-MDA state. This could
reflect that physicians were more likely to prescribe
corticosteroids in severe/difficult cases. On the other
hand, several authors have indicated that systemic
therapy with corticoids hinders the control of skin
manifestations and should therefore not be used rou-
tinely, but only for a limited period of time [28, 29].
Systemic use of corticosteroids improves skin psoriasis,
but their withdrawal triggers relapses in the form of a
“rebound effect”, producing recurrence of the skin
manifestations or transformation into the generalized
pustular form [28, 29].
Heterogeneity and complexity of PsA are challen-
ging for the clinical measure of the disease, both
from the patient’s perspective and from the physi-
cian’s view. Patients with PsA experience functional
impairment and reduced quality of life, so patient
global assessment in PsA is explained mainly by the
physical, but also by the psychological aspect, of the
disease [30]. PROs, such as the novel PsAID ques-
tionnaire [12], are important instruments to evaluate
healthcare interventions and to reflect the impact of
PsA on patients’ lives. There are few studies that have
reported results with this tool [31]. In the present
study, we observed that MDA state and lower impact
of the disease are associated. Thus, statistically signifi-
cant differences were observed between MDA and
non-MDA patients in all physical and psychological
PsAID domains. These findings suggest that PsAID
information seems to be in consonance with the MDA
state and could be a useful tool for assessing PsA from the
patient’s point of view.
An adequate therapeutic approach for PsA depends on
the type and severity of the skin and joint involvements [32].
Anti-TNF drugs have been shown to significantly inhibit
joint damage [33–35]. In the present study, MDA was
achieved by a significant proportion of patients (63%)
receiving anti-TNF or csDMARD monotherapy. Interest-
ingly, we found a lower, but not meaningful, proportion of
patients receiving anti-TNF concomitantly with csDMARDS
(52.5%) in the MDA state compared with those treated with
anti-TNF alone. This could be due to concomitant therapy
being administered to more severe patients who have more
difficulty achieving a MDA state.
Moreover, ad hoc analysis results from clinical trials
indicated that concomitant use of methotrexate and
anti-TNF was not more effective in achieving a response
[32, 36]. A recent study showed that methotrexate
administered in combination with etanercept in patients
with PsA may not provide significantly greater improve-
ment in arthritis or psoriasis symptoms than etanercept
monotherapy [36]. Despite the advances in therapy for
PsA, there remain many patients who fail to respond and
lose efficacy over time [32]. In the present study, 41.4% of
the patients did not achieve the MDA state, although
statistically significant differences were not observed
between non-MDA and MDA patients regarding the use
of non-biological DMARDs and biological DMARDs.
Some authors suggested that the TNFα pathway might
not have a pivotal role in driving the inflammation in such
patients, and these patients might benefit from other
treatments targeted at different inflammatory pathways
that are implicated in the disease activity [7, 32].
Some limitations derived from the cross-sectional
nature of this study should be borne in mind. PsA is
known to be a heterogeneous disorder, with progres-
sion highly variable between individuals. The data
presented here are a photograph of a specific moment
of the state of illness of patients with a long evolution
of the disease. We cannot be sure what proportion of
patients achieved MDA state due to the natural his-
tory of the disease and what success treatment had
on outcome. Thus, it is difficult to know whether the
management of these patients was as appropriate as it
should have been. Furthermore, we do not know the
proportion of patients who reached sustained MDA
and how long they remained in this state. A further
limitation is related to the study being designed to
include patients on conventional or biological DMARDs,
representing the majority of PsA cases followed in the
Rheumatology Department. PsA patients that only require
NSAIDs or corticosteroids are usually followed in general
practice and therefore they were not included.
Despite these limitations, this multicenter study shows
the treatment response of a representative Spanish popu-
lation with PsA in a routine clinical setting. In addition, a
further strength of this study is the use of the novel PsAID
questionnaire, which allowed a precise interpretation of
the patient-perceived impact of the disease.
To summarize, in this study we report that a signifi-
cant proportion of PsA patients achieve a MDA state in
normal clinical practice, reflecting a management of PsA
in Spain similar to that which has been published in
other countries. The PsAID could be an additional use-
ful tool to assess PsA interventions in clinical practice,
although further studies are needed to confirm it.
Conclusions
This study supports the use of MDA and PsAID as two
of the main assessment tools for PsA in routine clinical
practice.
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